Canadian drug companies want new pricing regs delayed again until after pandemic

  • 📰 CTVNews
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 99%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

Almost three dozen Canadian pharmaceutical companies made a direct appeal to Prime Minister Justin Trudeau last month to delay the new drug pricing regulations for a third time.

The companies, including all four of the drugmakers behind the COVID-19 vaccines being used in Canada now, want more time, and less pandemic distraction, to try and make their case to the Liberals that the regulations will do more harm than good.

It's estimated the changes could cut drug prices by $13 billion over the next 10 years, fulfilling the Liberal promise to make medicines more affordable to Canadians. "No Canadian should have to choose between paying for prescriptions and putting food on the table," said Aisling MacKnight. Pinnow said that goal is in jeopardy if the regulations go forward, because they are going to stifle private investment at a time when competition to grow life sciences industries is soaring.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

They want to know how far they can go in ripping people off for the medicine they need. Big Pharma hosing the little people, who can barely afford their medicine.

The cost of drugs is largely due to government standing in front of progress. You wanna lower drug pricing start lying off all these people that make the process slow as dirt. Some of them making $800,000 plus per yr and have nothing to do with innovation. IE mRNA is 15 yrs old.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 1. in BE

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Investor relations software company Q4 sets price range for $150-million IPOThe company is one of a slew of Canadian tech companies that have sought to tap public markets during the pandemic
La source: globeandmail - 🏆 5. / 92 Lire la suite »